Volitionrx Ltd (VNRX) Stock Price, Quote & News

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response a...

Industry: Medical Devices

Sector: Healthcare

Phone: 512 774 8930

Website: volition.com

Address:

1489 West Warm Springs Road, Suite 110, Henderson, United States

darfichdichmal Sep. 15 at 10:04 PM

$VNRX https://www.tipranks.com/news/company-announcements/volitionrx-reduces-debt-through-convertible-note-share-issuance?utm_source=webullapp.com&utm_medium=referral

0 · Reply

Lyn30 Sep. 15 at 1:19 PM

$VNRX They did RS in April 2026 They paid off of notes 12M float As per history of this type stocks, most ran 2.50+ from around this price imo My target big here

0 · Reply

martyn78 Sep. 15 at 10:03 AM

Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $CYAB / $VNRX joining my portfolio

0 · Reply

DubLad1976 Sep. 15 at 10:02 AM

$VNRX Needs to start turning. PR machine needs to be massively cranked up!

0 · Reply

ZacksSCR Sep. 14 at 8:18 PM

$VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Hum https://buff.ly/bHeGefB

0 · Reply

darfichdichmal Sep. 14 at 1:43 PM

$VNRX VolitionRx Fully Pays Off $7.5M Convertible Promissory Note, Dated May 20, 2025 https://www.webullapp.com/news-detail/15576684368577536?audioNewsPlayedDuration=&theme=1&color=2&hl=en&android_sdk_int=36&canary-version=&_v=1&sp=1&statusBarHeightV2=38&isLite=false&wbFontSetting=large&wbFontUnit=29&wbFontSize=35&isSubsNews=false

0 · Reply

Lyn30 Sep. 14 at 12:29 PM

$VNRX CTB 1100% it’s insane Big news came today

1 · Reply

Lyn30 Sep. 14 at 12:24 PM

$VNRX imo most undervalued and potential penny stock shouldn’t be in penny world Time to

0 · Reply

KoalaFlipper Sep. 13 at 7:24 PM

$VNRX 👀🙏

0 · Reply

Faykar Sep. 11 at 5:21 PM

$VNRX break it

0 · Reply

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

2026-09-10T12:26:49.000Z - 5 days ago

VolitionRx presents early stage I solid cancer detection at ESMO MAP Conference

Sep 10, 2026, 8:17 AM EDT - 5 days ago

Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference

Sep 10, 2026, 8:00 AM EDT - 5 days ago

VolitionRx Slides: Corporate presentation

Sep 9, 2026, 8:00 AM EDT - 6 days ago

VolitionRx Registration statement: Registration filing

Sep 8, 2026, 8:00 AM EDT - 7 days ago

VolitionRx Registration statement: Registration filing

2026-08-28T20:25:09.000Z - 18 days ago

VolitionRx files to sell 10.01M shares of common stock for holders

Aug 28, 2026, 8:00 AM EDT - 18 days ago

VolitionRx Registration statement: Registration filing

Aug 26, 2026, 9:17 AM EDT - 20 days ago

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

2026-08-26T12:26:48.000Z - 20 days ago

VolitionRx announces publication on Nu.Q NETs H3.1 biomarker

Aug 26, 2026, 8:17 AM EDT - 20 days ago

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

2026-08-17T09:38:03.000Z - 4 weeks ago

VolitionRx reports results from lateral flow finger prick sample test for sepsis

2026-08-16T14:09:56.000Z - 4 weeks ago

VolitionRx reports Q2 revenue $400K, consensus $474.34K

Aug 14, 2026, 8:30 AM EDT - 4 weeks ago

VolitionRx Earnings Call Transcript: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 4 weeks ago

VolitionRx Earnings release: Q2 2026

Aug 14, 2026, 8:30 AM EDT - 4 weeks ago

VolitionRx Quarterly report: Q2 2026

Aug 13, 2026, 4:10 PM EDT - 4 weeks ago

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

VolitionRx Slides: Corporate presentation

Aug 12, 2026, 8:17 AM EDT - 4 weeks ago

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

Aug 11, 2026, 4:10 PM EDT - 5 weeks ago

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

Aug 5, 2026, 8:17 AM EDT - 5 weeks ago

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

Aug 1, 2026, 8:00 AM EDT - 6 weeks ago

VolitionRx Slides: Corporate presentation

Jul 30, 2026, 8:17 AM EDT - 6 weeks ago

Volition Advances Nu.Q® NETs Platform Towards Commercialization

Jul 21, 2026, 7:00 AM EDT - 1 month ago

VolitionRx Slides: Corporate presentation

2026-07-10T21:35:11.000Z - 2 months ago

VolitionRx registers to sell 3.31M shares of common stock for holders

Jul 10, 2026, 8:00 AM EDT - 2 months ago

VolitionRx Registration statement: Registration filing

2026-07-07T12:35:41.000Z - 2 months ago

VolitionRx announces data on prognostic value of Nu.Q Cancer Assay

Jul 7, 2026, 8:17 AM EDT - 2 months ago

VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test

2026-06-18T12:46:44.000Z - 2 months ago

VolitionRx resumed with a Buy at Maxim

2026-06-17T12:21:03.000Z - 3 months ago

VolitionRx announces collaboration with Sysmex

Jun 17, 2026, 8:15 AM EDT - 3 months ago

VolitionRx Announces Collaboration with Sysmex

Jun 7, 2026, 6:30 PM EDT - 3 months ago

VolitionRx Announces Pricing of $4.6 Million Public Offering

2026-06-03T13:09:07.000Z - 3 months ago

VolitionRx files patent covering Nu.Q technology for Ebola triage

Jun 3, 2026, 8:12 AM EDT - 3 months ago

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

Jun 2, 2026, 8:00 AM EDT - 3 months ago

VolitionRx Proxy statement: Proxy filing

May 15, 2026, 8:30 AM EDT - 4 months ago

VolitionRx Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 4 months ago

VolitionRx Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 4 months ago

VolitionRx Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 4 months ago

VolitionRx Slides: Corporate presentation

2026-05-14T21:21:26.000Z - 4 months ago

VolitionRx reports Q1 revenue $1M, consensus $409,920

May 14, 2026, 4:10 PM EDT - 4 months ago

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

May 13, 2026, 8:00 AM EDT - 4 months ago

VolitionRx Proxy statement: Proxy filing

May 11, 2026, 8:19 AM EDT - 4 months ago

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

2026-05-07T06:07:48.000Z - 4 months ago

VolitionRx submits manuscript for Nu.Q Vet cancer test in cats

May 6, 2026, 8:17 AM EDT - 4 months ago

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

2026-04-29T14:40:22.000Z - 4 months ago

VolitionRx announces milestone in nucleosomes detection

Apr 29, 2026, 8:17 AM EDT - 4 months ago

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

2026-04-23T12:21:08.000Z - 4 months ago

VolitionRx’s compliance plan accepted by NYSE American

Apr 23, 2026, 8:12 AM EDT - 4 months ago

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

2026-04-20T12:05:06.000Z - 4 months ago

VolitionRx downgraded to Hold from Buy at D. Boral Capital

Apr 20, 2026, 7:30 AM EDT - 4 months ago

Volition Launches rNuQ™ Webshop Broadening Product Range

2026-04-02T16:11:44.000Z - 5 months ago

VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright

Apr 1, 2026, 8:30 AM EDT - 5 months ago

VolitionRx Earnings Call Transcript: Q4 2025

Apr 1, 2026, 8:30 AM EDT - 5 months ago

VolitionRx Annual report: Q4 2025

Apr 1, 2026, 8:30 AM EDT - 5 months ago

VolitionRx Earnings release: Q4 2025

Apr 1, 2026, 7:00 AM EDT - 5 months ago

VolitionRx Slides: Corporate presentation

Mar 31, 2026, 4:05 PM EDT - 5 months ago

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Mar 31, 2026, 8:16 AM EDT - 5 months ago

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Mar 30, 2026, 8:13 AM EDT - 5 months ago

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

Mar 26, 2026, 8:17 AM EDT - 5 months ago

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

Mar 25, 2026, 4:12 PM EDT - 5 months ago

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

2026-03-25T13:04:07.000Z - 5 months ago

Why is VolitionRX Stock (VNRX) Up 24% Today?

Mar 25, 2026, 8:17 AM EDT - 5 months ago

Volition Announces Detection of Over 95% of Early-Stage Cancers

Mar 18, 2026, 8:17 AM EDT - 6 months ago

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

2026-03-06T13:18:03.000Z - 6 months ago

VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems

Mar 6, 2026, 8:10 AM EST - 6 months ago

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Feb 25, 2026, 8:10 AM EST - 6 months ago

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Feb 11, 2026, 7:00 AM EST - 7 months ago

VolitionRx Proxy statement: Proxy Filing

Feb 10, 2026, 8:07 AM EST - 7 months ago

Volition Announces the Appointment of New Distributor for Nu.Q® Discover

Feb 9, 2026, 5:20 PM EST - 7 months ago

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 9, 2026, 7:00 AM EST - 7 months ago

VolitionRx Registration statement: Registration Filing

Feb 4, 2026, 8:45 AM EST - 7 months ago

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

Jan 30, 2026, 8:50 AM EST - 7 months ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Jan 27, 2026, 8:00 AM EST - 7 months ago

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

Jan 26, 2026, 7:00 AM EST - 7 months ago

VolitionRx Proxy statement: Proxy Filing

Jan 20, 2026, 8:25 AM EST - 7 months ago

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Jan 16, 2026, 8:45 AM EST - 8 months ago

Volition Sponsors Symposium at Veterinary Meeting and Expo

Jan 8, 2026, 9:15 AM EST - 8 months ago

VolitionRx Secures $2.0 Million in Funding

Jan 8, 2026, 8:45 AM EST - 8 months ago

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Jan 8, 2026, 7:00 AM EST - 8 months ago

VolitionRx Slides: Corporate Presentation

Dec 17, 2025, 8:45 AM EST - 9 months ago

Volition Issues Business Review 2025

Dec 11, 2025, 9:00 AM EST - 9 months ago

Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

Dec 8, 2025, 9:00 AM EST - 9 months ago

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

Dec 4, 2025, 9:00 AM EST - 9 months ago

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

Nov 25, 2025, 8:45 AM EST - 9 months ago

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

Nov 14, 2025, 8:30 AM EST - 10 months ago

VolitionRx Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

VolitionRx Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

VolitionRx Earnings release: Q3 2025

Nov 13, 2025, 4:10 PM EST - 10 months ago

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 8:45 AM EST - 10 months ago

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Oct 17, 2025, 8:00 AM EDT - 11 months ago

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

Oct 10, 2025, 8:30 AM EDT - 11 months ago

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 9, 2025, 4:05 PM EDT - 11 months ago

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 8, 2025, 11:00 AM EDT - 11 months ago

VolitionRx Transcript: Status Update

Oct 2, 2025, 8:45 AM EDT - 11 months ago

Volition Sponsors Upcoming GenomeWeb Webinar

Sep 29, 2025, 9:30 AM EDT - 11 months ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX

Sep 11, 2025, 7:00 AM EDT - 1 year ago

VolitionRx Slides: Corporate Presentation

Sep 9, 2025, 8:45 AM EDT - 1 year ago

Volition Signs First Human Out Licensing Deal

darfichdichmal Sep. 15 at 10:04 PM

$VNRX https://www.tipranks.com/news/company-announcements/volitionrx-reduces-debt-through-convertible-note-share-issuance?utm_source=webullapp.com&utm_medium=referral

0 · Reply

Lyn30 Sep. 15 at 1:19 PM

$VNRX They did RS in April 2026 They paid off of notes 12M float As per history of this type stocks, most ran 2.50+ from around this price imo My target big here

0 · Reply

martyn78 Sep. 15 at 10:03 AM

0 · Reply

DubLad1976 Sep. 15 at 10:02 AM

$VNRX Needs to start turning. PR machine needs to be massively cranked up!

0 · Reply

ZacksSCR Sep. 14 at 8:18 PM

0 · Reply

darfichdichmal Sep. 14 at 1:43 PM

0 · Reply

Lyn30 Sep. 14 at 12:29 PM

$VNRX CTB 1100% it’s insane Big news came today

1 · Reply

Lyn30 Sep. 14 at 12:24 PM

$VNRX imo most undervalued and potential penny stock shouldn’t be in penny world Time to

0 · Reply

KoalaFlipper Sep. 13 at 7:24 PM

$VNRX 👀🙏

0 · Reply

Faykar Sep. 11 at 5:21 PM

$VNRX break it

0 · Reply

Mike_Rotsch Sep. 11 at 2:55 PM

$VNRX Alright, looks like the double-bottom play isn't going to work. Toodles.

0 · Reply

Mdctrades Sep. 11 at 2:43 PM

$VNRX market pretty much green except

0 · Reply

dig_THAT_girl Sep. 10 at 6:35 PM

$VNRX call me crazy, but I just bought more to average down. It sure would be nice to see volition sell some damn product already!

0 · Reply

ihuntbiggame Sep. 10 at 4:23 PM

$VNRX These Analyst truly help DISTRIBUTE OUT! I am surprised NEEDHAM and CRAIG HALLUM did not get in on the action. The anlysts for $VUZI atleast had the DECENCY to stop attending the Coference Call In. VUZI James McIlree,Dawson James Securities,9.8 Years Christian Schwab,Craig-Hallum Capital Group,8.7 Years Michael Latimore,Northland Capital Markets,2.2 Years VNRX Bruce Jackson,The Benchmark Company,3.5 Years Justin Walsh,Jones Research,1.3 Years Steven Ralston,Zacks Small Cap Research,4 Years Ilya Zubkov,Freedom Capital Markets,1.5 Years Yi Chen,H.C. Wainwright & Co.,1.5 Years

0 · Reply

Mike_Rotsch Sep. 10 at 3:34 PM

$VNRX

0 · Reply

Mike_Rotsch Sep. 10 at 2:33 PM

$VNRX Alright you POS, it's time to fly now.

0 · Reply

darfichdichmal Sep. 10 at 1:42 PM

$VNRX https://www.tipranks.com/news/the-fly/volitionrx-presents-early-stage-i-solid-cancer-detection-at-esmo-map-conference-thefly-news?utm_source=webullapp.com&utm_medium=referral

0 · Reply

darfichdichmal Sep. 10 at 1:39 PM

$VNRX Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference PR Newswire09/10/2026 14:17 Follow Here's a summary of this article. VNRX +2.92% Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev., Sept. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract1 at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference (ESMO MAP) in London this week. The presentation entitled "Early stage I solid cancer detection by direct ChIP-seq of short CTCF-protected plasma ctDNA" and given by Dr. Andrew Retter, highlights the use of its Capture-Seq™ technology in the detection of early-stage I solid cancer. Dr Andrew Retter, Medical Consultant, Volition, said: "We were delighted to be selected to present in the main auditorium at this prestigious conference.

0 · Reply

Pukkaa56 Sep. 10 at 12:47 PM

$VNRX

0 · Reply

srvguitar Sep. 10 at 12:27 PM

$VNRX NEWS OUT

0 · Reply

Mike_Rotsch Sep. 9 at 7:04 PM

$VNRX Alright, yes. Here it comes.

0 · Reply

Faykar Sep. 9 at 2:31 PM

$VNRX She loves to make pump over ema50 over 15min. Double bottomed, volume is good today. 1st target is 0.47$

0 · Reply

Market Cap	4.26M
Revenue (ttm)	1.73M
Net Income (ttm)	-23.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,350.29%
Debt to Equity Ratio	-0.31

Volume	2,180,100
Avg Vol	9,623,344
Day's Range	N/A - N/A
Shares Out	13.65M
Stochastic %K	6%
Beta	1.10
Analysts	Strong Sell
Price Target	$14.28